表紙:抗てんかん薬の世界市場 (2021-2028年)
市場調査レポート
商品コード
972288

抗てんかん薬の世界市場 (2021-2028年)

Global Antiepileptic Drugs Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
抗てんかん薬の世界市場 (2021-2028年)
出版日: 2021年07月07日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界における抗てんかん薬の市場成長は、高齢者人口の増加よって推進されており、食生活は、世界の抗てんかん薬市場の成長をもたらす主な要因の一部となっています。加えて、多数のパイプライン薬が市場の成長をけん引しています。

当レポートでは、世界の抗てんかん薬市場について調査し、市場の概要、各セグメントおよび地域別の市場分析と予測、競合情勢の分析、主要企業のプロファイルなどを提供しています。

目次

第1章 世界の抗てんかん薬市場:調査範囲・手法

  • 調査手法
  • 調査目的・調査範囲

第2章 世界の抗てんかん薬市場:市場定義・概要

第3章 世界の抗てんかん薬市場:エグゼクティブサマリー

  • 市場内訳:医薬品別
  • 市場内訳:投与経路別
  • 市場内訳:流通チャネル別
  • 市場内訳:地域別

第4章 世界の抗てんかん薬市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の抗てんかん薬市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 医療費償還分析
  • アンメットニーズ

第6章 世界の抗てんかん薬市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19:以前の市場シナリオの前
    • COVID-19:現在の市場シナリオ
    • COVID-19:以降または将来のシナリオ
  • Covid-19における価格のダイナミクス
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の抗てんかん薬市場:医薬品別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):医薬品別
    • 市場魅力指数:医薬品別
  • 第一世代抗てんかん薬
  • 第二世代抗てんかん薬
  • 第三世代抗てんかん薬

第8章 世界の抗てんかん薬市場:投与経路別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):投与経路別
    • 市場魅力指数:投与経路別
  • 経口
  • 静脈内

第9章 世界の抗てんかん薬市場:流通チャネル別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):流通チャネル別
    • 市場魅力指数:流通チャネル別
  • 病院薬局
  • 薬局
  • その他

第10章 世界の抗てんかん薬:地域別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):地域別
    • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):医薬品別
    • 市場規模分析・前年比成長分析(%):投与経路別
    • 市場規模分析・前年比成長分析(%):流通チャネル別
    • 市場規模分析・前年比成長分析(%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界の抗てんかん薬:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第12章 世界の抗てんかん薬:企業プロファイル

  • GW Pharmaceuticals, plc
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.

第13章 重要考察

第14章 DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH2827

Market Overview

The global antiepileptic drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

The antiepileptic drugs are medications that are developed for the purpose of idiopathic and asymptomatic treatment of seizures and epilepsy. In addition to epilepsy and seizures, antiepileptic drugs can also be taken for the purpose of treatment of neuropathic pain.

Market Dynamics

The global antiepileptic drugs market growth is driven by the expanding base of geriatric population, dietary habits are some of the significant factors that are triggering growth of the global antiepileptic drugs market.

Large number of pipeline drugs is driving the growth of the market

The market is driven by advancement in drugs modification. Over the past several periods, the number of available antiepileptic drugs has more than doubled, many of the presently available antiepileptic drugs have basics pharmacokinetics and more small effects on liver metabolism that converts into a lower rate of side effects.

The large number of pipeline drugs is driving the growth of the market. The expected launch of drugs currently in the pipeline, such as Ganaxolone by Marinus Pharmaceuticals, Inc., Perampanel by Eisai Co., Ltd., USL261 by Upsher Smith Laboratories, Inc., and YKP3089 by SK Life Sciences, Inc. is a high impact rendering driver of the epilepsy drugs market.

VX765 by Vertex Pharmaceuticals, Inc. and YKP3089 by SK Life Sciences, Inc. are some of the Phase IIb drugs. Phase III clinical trials include NRL-1 intranasal Diazepam, Carbamazepine IV, Diazepam Auto-injector (Vanquix), and Topiramate Extended-Release (USL-255).

Rising awareness levels about epilepsy coupled with strategic alliances are anticipated to stimulate the market growth.

Increasing number of people being affected with different types of cancer is another factor driving the growth of the antiepileptic drug market. Chemotherapy is one of the standard treatments used to deal with cancer and is also accompanied by side effects of nausea and vomitting. In fact, chemotherapy actually accounts for the largest share of all the applications of the global antiepileptic drugs market. This factors are driving the growth of the market in the forecast period.

Rising generic competition is likely to hinder the market growth

However, the market is threatened by generic competition, which has risen dramatically in the face of patent expirations among various major branded antiepileptic drugs. This factor will hamper the market growth in the forecast period.

COVID-19 Impact Analysis

There is no evidence that people with epilepsy alone have a weakened immune system. They should not be considered "immunocompromised" and would not have an "immune deficiency" from having seizures. People with different types of epilepsy, certain causes of epilepsy or other health conditions may have factors affecting their immune system. However, patients with tumor-related, drug-resistant epilepsy, insomnia, and economic difficulties are at a higher risk of increased seizure frequency. Some people with epilepsy regardless of seizure control have other health conditions that put them at higher risk from COVID-19.

Segment Analysis

Second generation anti-epileptics segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The second-generation anti-epileptics drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions.

Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018, one of the market player UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.

In September 2019, GW Pharmaceuticals, plc, a biopharmaceutical company headquartered in the U.K., unveiled that it received approval from the European Commission (EC) for EPIDYOLEX, an innovative drug that will be used for Dravet syndrome or Lennox-Gastaut syndrome (LGS), as an adjunctive therapy of seizures. It is meant for patients who are 2 years of age and older. It will be launched across Europe. These factors are driving the growth of the market in the forecast period.

The hospital pharmacy are expected to dominate the antiepileptic drugs market during the forecast period

The hospital pharmacies held the largest share in the antiepileptic drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global antiepileptic drugs market

North America region is dominating the global antiepileptic drugs market accounted for the largest market share, owing to well-established health care infrastructure, technological advancements, and favorable government support in the region. The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer's disease. About one percent of Americans have some form of epilepsy, and nearly four percent (1 in 26) will develop epilepsy at some point in their lives. The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson's disease, and cerebral palsy combined. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the antiepileptic drugs market.

Competitive Landscape

The antiepileptic drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GW Pharmaceuticals, plc, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiepileptic drugs market globally.

Sanofi S.A

Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.

Product Portfolio: The Company's portfolio comprised of drugs, generic medicines, food supplement, cosmetics, and medical devices such as cancer, cardiology, gynecology, and diabetes.

Why Purchase the Report?

  • Visualize the composition of the antiepileptic drugs market segmentation by drugs, route of administration, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in antiepileptic drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Antiepileptic Drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global antiepileptic drugs market report would provide an access to an approx. 61 market data table, 55 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Antiviral Drugs Market - By Drugs

  • First Generation Anti-epileptics
  • Second Generation Anti-epileptics
  • Third Generation Anti-epileptics

Global Antiviral Drugs Market -By Route of Administration

  • Oral
  • Intravenous

Global Antiviral Drugs Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores
  • Other

Global Antiviral Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Antiepileptic Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Antiepileptic Drugs Market - Market Definition and Overview

3. Global Antiepileptic Drugs Market - Executive Summary

  • 3.1. Market Snippet by Drugs
  • 3.2. Market snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Antiepileptic Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the new drug approvals over the past few years
      • 4.1.1.2. Increase in the Cases of Epilepsy
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Antiepileptic Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Antiepileptic Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Antiepileptic Drugs Market - By Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Segment
    • 7.1.2. Market Attractiveness Index, By Drugs Segment
  • 7.2. First Generation Anti-epileptics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Second Generation Anti-epileptics
  • 7.4. Third Generation Anti-epileptics

8. Global Antiepileptic Drugs Market - By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Intravenous

9. Global Antiepileptic Drugs Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Pharmacy Stores
  • 9.4. Other

10. Global Antiepileptic Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6.
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Antiepileptic Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Antiepileptic Drugs Market- Company Profiles

  • 12.1. GW Pharmaceuticals, plc, *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Abbott Laboratories
  • 12.3. GlaxoSmithKline PLC
  • 12.4. Johnson & Johnson
  • 12.5. Novartis AG
  • 12.6. Pfizer, Inc.
  • 12.7. Sanofi SA
  • 12.8. Sunovion Pharmaceuticals Inc.
  • 12.9. Takeda Pharmaceutical Company Limited
  • 12.10. UCB S.A.

LIST NOT EXHAUSTIVE

13. Global Antiepileptic Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us